US › Healthcare

Inhibikase Therapeutics Inc (IKT)

US · Healthcare · Biotechnology

$2.44+10.41%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-16.4M
Profit YoY
-19.8%
EPS
$-0.10
EPS estimate
$-0.09

EPS came in at -0.10 against a street estimate of -0.09 — a miss of 5.7%.

Key statistics

Market cap
$342.3M
Forward P/E
0.0
P/B
2.03
Book value
$0.98
EPS (TTM)
$-0.44
52-week high
$2.53
52-week low
$1.33
50-day MA
$1.92
200-day MA
$1.77
Beta
0.94

Analyst view

Analysts rate Inhibikase Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.00.

Shareholding

Insiders
5.40%
Institutions
91.85%

Largest institutional holders

FundStake
Sands Capital Ventures, LLC8.29%
Soleus Capital Management, L.P.6.93%
Fairmount Funds Management LLC5.49%
Trails Edge Capital Partners, LP5.13%
ADAR1 Capital Management LLC4.21%
Kalehua Capital Management LLC4.14%
BlackRock Inc4.01%
Blackstone Inc3.78%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Inhibikase Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.